President Trump plans to impose a 100% tariff on imported generic drugs from August 2028, rising to 200% after a year, aiming to reshore U.S. pharmaceutical production, with experts warning of potential price increases and shortages.
U.S. President Donald Trump's proposed tariffs on generic drugs will raise medicine prices for American patients, according to Dr. Reddy's Laboratories CEO Erez Israeli. Indian drugmakers, who supply nearly half of U.S. generics, cannot absorb 100-200% tariffs due to thin margins, and relocating operations to the U.S. is deemed unfeasible and too lengthy.
US Secretary of State Marco Rubio anticipates India's concern regarding new generic drug import tariffs announced by President Trump, which will increase significantly after August 1, 2026. The issue was not raised with India's External Affairs Minister S Jaishankar during their recent meeting, though it might have been discussed with other US officials.
US President Trump announced 100-200% tariffs on generic medicines from Aug 2028 unless manufacturing relocates to the US. This poses a significant challenge for India's $30B pharma industry, which supplies 47% of US generic prescriptions, potentially making exports unviable and raising US drug prices.
Donald Trump's proposed 200% tariff on generic drug imports raises concerns for Indian pharma, but experts suggest a limited long-term impact due to India's cost advantage, US dependence on imports, and lengthy factory approval timelines, making large-scale manufacturing shifts difficult.
The European Commission expects EU generic medicines to be exempt from new U.S. tariffs announced by Donald Trump, citing a 2025 transatlantic trade deal. Trump's plan, aiming to boost U.S. pharmaceutical production, proposes 100% tariffs on generic drugs by 2028, escalating to 200% in 2029.
President Trump proposed tariffs up to 200% on imported generic medicines after a two-year grace period, aiming to boost U.S. production. The generic drug industry, operating on thin margins, warns that shifting manufacturing domestically within the timeframe is challenging and could lead to market exits or price increases, impacting patient access to affordable medicines.
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could pressure Indian pharmaceutical exporters, but India's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).
President Trump announced a new tariff schedule for generic drugs, starting with two years of zero tariffs, then a 100% levy in August 2028, rising to 200% in 2029. This policy aims to incentivize generic drugmakers to move production to the U.S., significantly impacting countries like India, which supplies nearly 50% of U.S. generic medicines.
President Trump plans 100-200% tariffs on generic drugs by 2028 to reshore production, impacting Indian pharma. US and China are set for AI talks amid IP theft concerns. US strikes Iran for an 11th night as Secretary Rubio questions Iran's seriousness in peace talks. Alphabet and Tesla earnings are also due.
President Trump announced zero tariffs on imported generic drugs for two years starting August 1, aiming to incentivize onshore production. Tariffs will then escalate to 100% in 2028 and 200% in 2029 for non-compliant companies, while patented drug tariffs remain unchanged.
The Trump administration is adding over 600 generic drugs to its TrumpRx website, aiming to lower prescription costs. The platform now features tools to find the cheapest local pharmacies and offers home delivery, partnering with companies like Mark Cuban's Cost Plus Drug Company and Amazon Pharmacy.
The Supreme Court is hearing Hikma v. Amarin, a case that could reshape generic drug pricing by determining whether generic manufacturers can be held liable for patent infringement when marketing medications for unpatented uses. The dispute centers on 'skinny labeling,' a strategy that has saved Medicare nearly $15 billion between 2015-2021 by bringing cheaper generics to market years before brand-name patents expire. A ruling in favor of Amarin could increase legal risks for generic companies, potentially leading to higher drug prices and longer waits for affordable medications.
China's volume-based procurement policy forces multinational drug companies to lower prices for public hospital purchases while allowing biotech firms to charge premium prices in the private market. The dual-track system benefits internet healthcare platforms and private healthcare providers like Alibaba Health, Yifeng and Hygeia, according to Citi research.
China's volume-based procurement policy, which mandates bulk drug purchases for public hospitals, is intensifying price competition for multinational pharmaceutical companies while creating more profitable channels for domestic biotech firms in the private market. Analysts note potential benefits for internet healthcare platforms, pharmacies, and private hospital services.
